238 related articles for article (PubMed ID: 28885361)
41. [Efficacy of imatinib in FIP1L1-PDGFRA positive hypereosinophilic syndrome].
Menif S; Ben Romdhane N; Hafsia R
Rev Med Interne; 2008 Jan; 29(1):65-7. PubMed ID: 18036706
[TBL] [Abstract][Full Text] [Related]
42. Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease.
Elling C; Erben P; Walz C; Frickenhaus M; Schemionek M; Stehling M; Serve H; Cross NC; Hochhaus A; Hofmann WK; Berdel WE; Müller-Tidow C; Reiter A; Koschmieder S
Blood; 2011 Mar; 117(10):2935-43. PubMed ID: 21224473
[TBL] [Abstract][Full Text] [Related]
43. [Efficiency of imatinib in polyserositis revealing a FIP1L1-PDGFRA-negative hypereosinophilic syndrome].
Green L; Kahn JE; Dufour JF; Le Scanff J; Charhon A; Broussolle C; Sève P
Rev Med Interne; 2010 Apr; 31(4):305-8. PubMed ID: 20167399
[TBL] [Abstract][Full Text] [Related]
44. Platelet-derived growth factor receptor inhibition to treat idiopathic hypereosinophilic syndrome.
Stone RM; Gilliland DG; Klion AD
Semin Oncol; 2004 Apr; 31(2 Suppl 6):12-7. PubMed ID: 15175999
[TBL] [Abstract][Full Text] [Related]
45. Rapid reversion of Loeffler's endocarditis by imatinib in early stage clonal hypereosinophilic syndrome.
Rotoli B; Catalano L; Galderisi M; Luciano L; Pollio G; Guerriero A; D'Errico A; Mecucci C; La Starza R; Frigeri F; Di Francia R; Pinto A
Leuk Lymphoma; 2004 Dec; 45(12):2503-7. PubMed ID: 15621768
[TBL] [Abstract][Full Text] [Related]
46. The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease.
Yamada Y; Rothenberg ME; Lee AW; Akei HS; Brandt EB; Williams DA; Cancelas JA
Blood; 2006 May; 107(10):4071-9. PubMed ID: 16418325
[TBL] [Abstract][Full Text] [Related]
47. The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia.
Cools J; Stover EH; Wlodarska I; Marynen P; Gilliland DG
Curr Opin Hematol; 2004 Jan; 11(1):51-7. PubMed ID: 14676627
[TBL] [Abstract][Full Text] [Related]
48. Management of hypereosinophilic syndrome: a prospective study in the era of molecular genetics.
Dahabreh IJ; Giannouli S; Zoi C; Zoi K; Voulgarelis M; Moutsopoulos HM
Medicine (Baltimore); 2007 Nov; 86(6):344-354. PubMed ID: 18004179
[TBL] [Abstract][Full Text] [Related]
49. Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia.
Score J; Curtis C; Waghorn K; Stalder M; Jotterand M; Grand FH; Cross NC
Leukemia; 2006 May; 20(5):827-32. PubMed ID: 16498388
[TBL] [Abstract][Full Text] [Related]
50. Successful Heart Transplantation for Unreversible Endomyocardial Fibrosis Related to FIP1L1-PDGFRA Chronic Eosinophilic Leukemia.
Fassnacht F; Roumier M; Fouret P; Levy V; Varnous S; Russel S; Lefevre G; Kahn JE
Transplantation; 2015 Nov; 99(11):e176-7. PubMed ID: 26492057
[No Abstract] [Full Text] [Related]
51. Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate.
Coutré S; Gotlib J
Semin Cancer Biol; 2004 Aug; 14(4):307-15. PubMed ID: 15305431
[TBL] [Abstract][Full Text] [Related]
52.
Sato M; Kato R; Jokoji R; Tachibana I
BMJ Case Rep; 2021 May; 14(5):. PubMed ID: 34045202
[TBL] [Abstract][Full Text] [Related]
53. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study.
Metzgeroth G; Walz C; Erben P; Popp H; Schmitt-Graeff A; Haferlach C; Fabarius A; Schnittger S; Grimwade D; Cross NC; Hehlmann R; Hochhaus A; Reiter A
Br J Haematol; 2008 Dec; 143(5):707-15. PubMed ID: 18950453
[TBL] [Abstract][Full Text] [Related]
54. Long-term outcomes of imatinib in patients with FIP1L1/ PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China.
Qu SQ; Qin TJ; Xu ZF; Zhang Y; Ai XF; Li B; Zhang HL; Fang LW; Pan LJ; Hu NB; Xiao ZJ
Oncotarget; 2016 May; 7(22):33229-36. PubMed ID: 27120808
[TBL] [Abstract][Full Text] [Related]
55. [Complete remission of an idiopathic hypereosinophilic syndrome while using imatinib].
Wolf D; Gastl G; Rumpold H
Dtsch Med Wochenschr; 2004 Oct; 129(40):2104-6. PubMed ID: 15455302
[TBL] [Abstract][Full Text] [Related]
56. The hypereosinophilic syndromes: current concepts and treatments.
Gleich GJ; Leiferman KM
Br J Haematol; 2009 May; 145(3):271-85. PubMed ID: 19243381
[TBL] [Abstract][Full Text] [Related]
57. Detection of FIP1L1-PDGFRA fusion by FISH.
Ma ES; Wong KF; Wong CL; Siu LL
Br J Haematol; 2007 Aug; 138(3):279. PubMed ID: 17542982
[No Abstract] [Full Text] [Related]
58. A novel FOXP1-PDGFRA fusion gene in myeloproliferative neoplasm with eosinophilia.
Sugimoto Y; Sada A; Shimokariya Y; Monma F; Ohishi K; Masuya M; Nobori T; Matsui T; Katayama N
Cancer Genet; 2015 Oct; 208(10):508-12. PubMed ID: 26319757
[TBL] [Abstract][Full Text] [Related]
59. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.
Cools J; DeAngelo DJ; Gotlib J; Stover EH; Legare RD; Cortes J; Kutok J; Clark J; Galinsky I; Griffin JD; Cross NC; Tefferi A; Malone J; Alam R; Schrier SL; Schmid J; Rose M; Vandenberghe P; Verhoef G; Boogaerts M; Wlodarska I; Kantarjian H; Marynen P; Coutre SE; Stone R; Gilliland DG
N Engl J Med; 2003 Mar; 348(13):1201-14. PubMed ID: 12660384
[TBL] [Abstract][Full Text] [Related]
60. Loeffler endocarditis in chronic eosinophilic leukemia with FIP1L1/PDGFRA rearrangement: full recovery with low dose imatinib.
Kim DS; Lee S; Choi CW
Korean J Intern Med; 2018 May; 33(3):642-644. PubMed ID: 28651427
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]